Hologic Set for Further Molecular Diagnostic Strength in Fiscal 2021; No Change to our FVE

Under CEO Stephen MacMillans' watch, Hologic has been able to focus on structural competitive advantages, improve its balance sheet, and judiciously step into complimentary markets, which evens out the vagaries of product cycles. Hologic controls roughly 65% of the U.S. digital mammography market and leads the way in first 3D mammography. While 3D adoption has slowed, Hologic's clinical data still gives it an edge over its larger competitors, and there are still opportunities to sell ancillary accessories for mammograms and biopsies.